As More Products Get Priority Review, User Fee Cost Gap From Standard Review Is Narrowing

 
• By Derrick Gingery
Priority seats
The FDA has been conducting an increasing number of priority assessments of NME NDAs and BLAs in recent years. • Source: Alamy

More from User Fees

More from Pathways & Standards